Gloucester Pharmaceuticals

About:

Gloucester Pharmaceuticals acquires clinical-stage oncology drug candidates and advances them through approvals and commercialization.

Website: http://www.gloucesterpharma.com

Top Investors: Apple Tree Partners, Rho Capital Partners, Novo Ventures, CIBC Capital Partners, Prospect Venture Partners

Description:

Gloucester Pharmaceuticals is a biopharmaceutical company owned by [Celgene](/organization/celgene) that acquires clinical-stage oncology drug candidates with the goal of advancing them through regulatory approval and commercialization. Gloucester's first compound, romidepsin, is a late-stage oncology drug candidate that has shown potential activity across a range of hematological malignancies. The Company retains worldwide exclusive rights to romidepsin, an oncology candidate within a new class of anti-cancer agents known as histone deacetylase (HDAC) inhibitors. Preclinical studies suggest that romidepsin is a potent inhibitor of Class I, Class II and Class IV HDACs.